Black Cohosh: History and Traditional Use

Black cohosh (Actaea racemosa L., long known as Cimicifuga racemosa) is a tall woodland perennial of the buttercup family, native to the eastern forests of North America. Its dark, knotted rhizome was a women's medicine in several Native American nations long before European contact, and from the colonial era onward it travelled into the American botanical pharmacopoeia, into one of the most famous patent medicines ever sold, and — from 1956 in Germany — into the modern world of standardized, clinically studied menopause remedies. This is the story of how a roadside-shy forest plant became one of the most-studied herbs in the world for the menopausal transition, told plainly and with each specific claim checked against the record.

Table of Contents

  1. Botanical Naming and the Many Folk Names
  2. Native American Traditions
  3. Colonial Adoption and the U.S. Pharmacopoeia
  4. Eclectics, Thomsonians, and Lydia Pinkham
  5. The German Era and the Birth of Remifemin
  6. The Phytoestrogen Question and Its Reappraisal
  7. Liver Safety and the Adulteration Problem
  8. From Tradition to Modern Research
  9. Research Papers and References
  10. Connections
  11. Featured Videos

Botanical Naming and the Many Folk Names

Black cohosh is the common English name for Actaea racemosa L., a member of the buttercup family (Ranunculaceae) native to rich, shaded woodlands from Ontario and the northeastern United States south through the Appalachians. Carl Linnaeus first published the name Actaea racemosa in his Species Plantarum of 1753; the genus name Actaea is an old classical plant name and the epithet racemosa describes the plant's long, tapering flower spike (a raceme). In 1818 the botanist Thomas Nuttall moved the species into the genus Cimicifuga, creating the combination Cimicifuga racemosa — the name under which the herb was known throughout most of its medical history and which still appears on many supplement labels and in older studies. Late-twentieth-century morphological and molecular work concluded that the plant sits more naturally within Actaea, and the species was reclassified back to Actaea racemosa around 1998, restoring Linnaeus's original placement.

The genus name Cimicifuga is itself a clue to one of the plant's oldest non-medical reputations: it derives from Latin cimex (bug) and fugare (to drive away), which is also the source of the English folk name bugbane — the strongly scented flowers were said to repel insects. Several other common names record what people noticed about the plant: black snakeroot and the related folklore use against snakebite; rattle-top or rattleweed, from the dry seeds rattling inside the ripe follicles; and fairy candle, for the tall white flowering wand. In nineteenth-century American medical texts it was also written up under the names macrotys and as the older "squaw root" — a once-common label, now widely recognized as a derogatory term, that nonetheless reflects the herb's long association with women's medicine.

The common element cohosh is generally traced to an Algonquian source — commonly reconstructed from an Eastern Abenaki or Penobscot word said to mean "rough" — thought to refer to the gnarled, knotty texture of the plant's rhizome. The same word stem is shared with the unrelated blue cohosh (Caulophyllum thalictroides), and the two plants are frequently and dangerously confused; they are botanically distinct and are not interchangeable. This thicket of names — classical, descriptive, and Indigenous — is itself a kind of record: it shows a plant familiar enough, and useful enough, to be re-named by nearly every community that lived alongside it.

Back to Table of Contents

Native American Traditions

Black cohosh's documented medicinal career begins with the Indigenous peoples of eastern North America, who used the rhizome long before European settlers recorded it. The ethnobotanical record — drawn from later written accounts and oral histories — describes use among several nations including the Cherokee, the Iroquois (Haudenosaunee), and Algonquian-speaking peoples such as the Delaware. The dominant and most consistently recorded theme is women's reproductive health: traditions hold that the root was used for menstrual difficulties, to ease the pains of childbirth, and to aid recovery afterward. Because these are records of past cultural practice rather than modern clinical findings, they are presented here as tradition.

Beyond gynecological use, the historical record attributes a notably broad range of applications to black cohosh across different nations and observers. The root was traditionally taken for rheumatism and joint pain — the Iroquois are recorded as using a root decoction, including as a soak for aching limbs — and it was used for general malaise, sore throat, kidney complaints, and coughs or chest trouble. The "black snakeroot" name carries an associated folk use against snakebite. As with many widely traded medicinal roots, the exact preparation and indication varied from nation to nation, and not every claim can be tied to a single documented source; the through-line that recurs most reliably, and that European medicine eventually fixed on, is the use in women's reproductive complaints and in rheumatic pain.

What makes this Indigenous record historically important is that it is the headwaters of essentially everything that follows. The colonial physicians, the nineteenth-century Eclectics, the patent-medicine makers, and ultimately the German pharmaceutical chemists all inherited — directly or indirectly — a use that began with Native American healers: a forest root for the disorders of the female reproductive cycle. Readers should note that historical ethnobotanical accounts describe practice in the past tense and are not treatment recommendations.

Back to Table of Contents

Colonial Adoption and the U.S. Pharmacopoeia

European settlers encountered black cohosh as a North American plant with an established Indigenous reputation, adopted it into their own practice during the colonial and early-republic periods, and carried dried rhizome back across the Atlantic. By the early nineteenth century the herb had moved from frontier folk remedy into the formal written record of American medicine. The root entered the United States Pharmacopoeia — the official national listing of recognized drugs — appearing under the name "black snakeroot" in its first edition of 1820 and remaining an official entry for roughly a century. (Standard reference reviews give the official period as approximately 1820 to the 1920s–1930s; the exact closing date differs slightly between sources, so the span is best stated as "from 1820 until the early twentieth century.")

In this period American physicians prescribed black cohosh for much the same cluster of complaints recorded in the Indigenous tradition, now described in the medical language of the day: as an emmenagogue to promote suppressed or painful menstruation, to relieve pain after childbirth, and as a remedy for the inflammation and pain of rheumatism and arthritis. Nineteenth-century sources also record its use for snakebite, for "inflamed lungs," and for chorea (St. Vitus' dance). The herb's reputation as a women's tonic and an anti-rheumatic was well enough established that it became a fixture of the era's domestic and professional medicine alike.

This formal recognition matters historically because it marks black cohosh's passage from a gathered folk medicine into an officially catalogued drug of the American mainstream — the same trajectory followed by a handful of other native plants such as echinacea. When the herb later faded from the official pharmacopoeia in the early twentieth century, as synthetic drugs rose and the older botanical schools declined, the accumulated knowledge did not vanish; it passed into the patent-medicine trade and the surviving herbal traditions, and eventually into the European clinical work that would revive it.

Back to Table of Contents

Eclectics, Thomsonians, and Lydia Pinkham

In nineteenth-century America, two reform movements built their practice around native botanical medicines, and both embraced black cohosh. The Thomsonian movement, founded on Samuel Thomson's system of plant-based domestic medicine, and the more professionalized Eclectic physicians both used the root extensively. The Eclectics in particular wrote it up in clinical detail; the herb was discussed in their literature under the name macrotys as well as black cohosh, and was valued as a remedy for rheumatism, for painful and suppressed menstruation, for the aftermath of childbirth, and for muscular and nervous complaints. John King, a leading Eclectic author and professor at the Eclectic Medical Institute in Cincinnati, was among the physicians who promoted it. These nineteenth-century professional texts are named here as historical sources rather than as modern citations.

Black cohosh reached its widest public fame not through physicians but through a bottle. Lydia E. Pinkham's Vegetable Compound, first marketed in the mid-1870s and one of the best-selling proprietary "women's tonics" of the late nineteenth and early twentieth centuries, listed black cohosh among its original botanical ingredients (alongside plants such as life root, unicorn root, pleurisy root, and fenugreek, suspended in a substantial amount of alcohol). Marketed directly to women for "female complaints" — menstrual discomfort, the troubles of menopause, and more — the Compound made black cohosh a household name and cemented, in the popular mind, the herb's identity as a women's remedy. Of all the plants in Pinkham's formula, black cohosh is the one that modern herbalists and researchers have studied most.

The Eclectic-and-patent-medicine era is the bridge in black cohosh's history. It carried the Indigenous women's-medicine tradition through the period when official scientific medicine was turning toward synthetic drugs, kept the herb in continuous popular use, and handed it — reputation intact — to the twentieth-century European researchers who would put it on the clinical-trial bench.

Back to Table of Contents

The German Era and the Birth of Remifemin

The modern chapter of black cohosh's history is largely a German one. German physicians and herbalists had used the plant since the late nineteenth century, but the decisive moment came in 1956, when the first standardized medicinal product made from black cohosh — Remifemin, manufactured by Schaper & Brümmer in Salzgitter, Germany — became available. Rather than a loose dried-root powder of uncertain strength, Remifemin was a defined extract (later standardized as an isopropanolic Cimicifuga racemosa extract, abbreviated iCR), which made consistent dosing and, crucially, formal clinical study possible.

From that point the herb accumulated an unusually deep evidence base for a botanical. The published review marking sixty years of these products notes that clinical investigation began with observational studies in the 1950s through 1970s, moved to controlled trials from the 1980s, and produced its first placebo-controlled study in 1986; by the 2010s, dozens of clinical studies involving more than eleven thousand patients had been published, the great majority using the standardized isopropanolic extract. This body of work made black cohosh one of the most-studied herbal medicines in the world for the menopausal transition, with vasomotor symptoms — hot flashes, sweating, and associated sleep disturbance — the indication most consistently reported to improve. Germany's official herbal-medicine advisory body, the Commission E, approved black cohosh for menopausal and menstrual complaints, lending it formal regulatory standing in Europe.

It is worth being honest that the clinical evidence, though large, is not unanimous: the herb's effectiveness for menopausal symptoms remains genuinely debated. A 2012 Cochrane systematic review of sixteen randomized trials concluded there was insufficient evidence to support its use, a finding that manufacturers and other researchers have contested in turn. The detailed clinical picture — what the trials show, where they agree and disagree, and how black cohosh compares with other options — is the subject of the companion Benefits articles; the historical point here is simply that the German standardized-extract era transformed black cohosh from a traditional root into a clinically scrutinized phytomedicine.

Back to Table of Contents

The Phytoestrogen Question and Its Reappraisal

For most of the twentieth century, a single assumption shaped how black cohosh was understood: that it worked, like soy or red clover, as a phytoestrogen — a plant compound mimicking the body's own estrogen. The idea was intuitive. The herb relieved exactly the symptoms of estrogen withdrawal, and mid-century chemists analyzing women's botanical tonics reported estrogen-like activity in their ingredients. For decades the herb was described, marketed, and feared accordingly, with the natural worry that an estrogenic plant might be risky for women with hormone-sensitive conditions such as breast cancer.

That picture was overturned by more rigorous laboratory work, particularly after about 2002. Careful receptor-binding studies and gene-expression analyses found that standardized black cohosh extract does not meaningfully bind the estrogen receptors (ER-alpha or ER-beta) and does not behave like an estrogen in estrogen-responsive tissue. Attention shifted to other mechanisms — effects on serotonergic, dopaminergic, GABAergic, and opioid pathways that are relevant to temperature regulation and mood — offering a non-hormonal explanation for the relief of hot flashes. The 2012 review pointedly titled Black cohosh: coming full circle? argued that researchers, fixed on the hormonal hypothesis, had overlooked the plant's oldest documented use — as a remedy for pain — and that black cohosh may act in part as an antinociceptive (pain-modulating) agent, in effect bringing the science back around to the rheumatism-and-pain tradition the Eclectics had recorded.

This reappraisal is one of the more striking arcs in herbal medicine: a remedy assumed for a century to act one way, shown by modern methods to act another, and in the process partly vindicating its earliest historical indications. The mechanism remains an active area of research, and the detailed pharmacology is covered in the companion Hormonal Balance article; for the history, the lesson is that tradition sometimes encodes a truth that a later, confident theory obscures.

Back to Table of Contents

Liver Safety and the Adulteration Problem

No honest history of black cohosh can skip the liver-safety question, because it has shaped the herb's modern reputation and the regulations attached to it. Beginning in the late 1990s and 2000s, a number of case reports linked black cohosh products to liver injury, and several national regulators responded by requiring cautionary labeling. The U.S. National Library of Medicine's LiverTox database classifies products marketed as black cohosh as a recognized cause of clinically apparent liver injury — while adding the crucial caveat that the specific responsible component is unclear.

The reason for that caveat is a long-running adulteration problem. Genuine Actaea racemosa is a slow-growing North American forest plant, and the supplement market has been repeatedly found to contain cheaper Asian Actaea (formerly Cimicifuga) species — such as Actaea dahurica, Actaea cimicifuga, and Actaea heracleifolia — substituted or mixed in. This means that some products blamed for liver harm may not have contained authentic black cohosh at all, which badly complicates any attempt to pin the injury on the true plant. Meanwhile, several causality re-analyses by Teschke and colleagues of the reported cases concluded that a convincing causal link to genuine black cohosh was rarely established, and a 2011 meta-analysis by Naser and colleagues of randomized controlled trials of the standardized isopropanolic extract found no evidence of adverse effects on liver function.

The honest summary, then, is a nuanced one that the historical record supports: liver injury has been reliably associated with some products sold as black cohosh, but a clear, dose-dependent toxicity of the authentic, correctly identified herb has not been demonstrated, and contamination or species substitution is a leading suspect in many of the worst cases. The practical legacy is the modern emphasis on verified species identity (via DNA or chemical fingerprinting), on reputable manufacturers, and on caution in anyone with liver disease — guidance set out in full in the main Black Cohosh article's cautions section.

Back to Table of Contents

From Tradition to Modern Research

The arc of black cohosh's history is unusually clean. It begins with Native American healers using a forest rhizome for the disorders of the female reproductive cycle and for rheumatic pain. It passes through colonial adoption and a century in the official U.S. Pharmacopoeia, through the Eclectic physicians and the runaway success of Lydia Pinkham's Vegetable Compound, and into the German standardized-extract era that began in 1956 and turned the herb into one of the most-studied botanicals in the world for the menopausal transition. Along the way the dominant scientific theory about how it works was raised, tested, and largely overturned — and the overturning pointed back, intriguingly, toward the pain-relieving use the tradition had recorded first.

Modern phytochemistry has given that long tradition a chemical address. Researchers have catalogued the rhizome's major constituents — the cycloartane-type triterpene glycosides (such as actein, 23-epi-26-deoxyactein, cimiracemoside, and cimigenol), the cinnamic-acid esters, and trace compounds — and laboratory work continues to probe how these molecules act on the nervous-system pathways relevant to hot flashes, mood, and pain rather than on the estrogen receptor. The detailed chemistry and the clinical evidence for each benefit are taken up in the companion Benefits hub and its sub-articles on menopausal hot flashes, mood and sleep, and bone health.

For the reader, the history is worth knowing because it explains both the promise and the cautions. A plant trusted by many cultures for women's health, refined into a measured medicine, and studied in thousands of patients is not a fad — but it is also not a proven cure, its effectiveness is still debated, and the supplement aisle contains imposters. Tradition raised the questions; research is still testing the answers. That continuity — a quiet woodland root used the same way across centuries, and only now being explained — is what makes the history of black cohosh worth telling.

Back to Table of Contents

Research Papers and References

The list below combines key peer-reviewed reviews and analyses bearing on the history, mechanism, and safety of black cohosh (Actaea racemosa / Cimicifuga racemosa) with curated PubMed topic-search links into the broader literature. Historical primary sources (Linnaeus's Species Plantarum, Nuttall's reclassification, nineteenth-century Eclectic texts, and the marketing record of Lydia Pinkham's Vegetable Compound) are named in the article as historical sources rather than as modern citations. Author names, titles, and journals are given as plain text; only stable identifiers (DOI, PMID, PubMed searches, and an NCBI Bookshelf record) are hyperlinked, each opening in a new tab.

  1. Henneicke-von Zepelin HH. 60 years of Cimicifuga racemosa medicinal products: clinical research milestones, current study findings and current development. Wiener Medizinische Wochenschrift. 2017;167(7-8):147-159. — doi:10.1007/s10354-016-0537-z (PMID: 28155126)
  2. Johnson TL, Fahey JW. Black cohosh: coming full circle? Journal of Ethnopharmacology. 2012;141(3):775-779. — doi:10.1016/j.jep.2012.03.050 (PMID: 22504147)
  3. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database of Systematic Reviews. 2012;(9):CD007244. — doi:10.1002/14651858.CD007244.pub2 (PMID: 22972105)
  4. Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte KU, Osmers R. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause. 2011;18(4):366-375. — doi:10.1097/gme.0b013e3181fcb2a6 (PMID: 21228727)
  5. Black Cohosh. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; updated 2025. — NCBI Bookshelf: NBK547990
  6. Black cohosh ethnobotany and traditional Native American use — PubMed: black cohosh ethnobotany traditional use
  7. Black cohosh for menopausal symptoms — clinical trials and reviews — PubMed: black cohosh menopause clinical trials

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents